CA-PULSESG
20.10.2021 15:02:13 CEST | Business Wire | Press release
pulsESG™ today announced the launch of its enterprise environmental, social, and governance (ESG) software as a service (SaaS) platform backed by $8.5 million in seed funding from leading impact-driven investors and led by two Silicon Valley enterprise software veterans. The platform distinguishes itself in the marketplace through features such as model-driven architecture and full integration with both internal sources of data and external investor-facing systems, empowering companies to track and derive insights for ESG compliance and improvement based on stakeholder requirements. The company emerged from stealth mode today and the product is expected to be made generally available in Q1 2022.
Led by tech veterans and co-founders Murat Sönmez and Inderjeet Singh, the pulsESG™ platform is designed to take a different approach to ESG analysis than what currently exists in the marketplace by providing comprehensive, auditable, and accurate deep analytics that can be integrated with both the source and destination ESG systems of customers. This new level of information empowers enterprises to make more informed ESG decisions using a platform that also provides end-users the flexibility to modify it based on changes in the ESG regulatory landscape and according to their stakeholder needs.
“Amidst changing impact benchmarks at national and global levels, accurate and reliable ESG analysis is moving from ‘nice-to-have’ to ‘must-have’ for enterprises worldwide, so we sought to develop a platform to help customers navigate this fluid landscape,” explained Co-founder, President, and CTO Inderjeet Singh. “The pulsESG™ platform was designed to raise the bar on quality and timeliness, allowing customers to respond to changes in the ESG models themselves, not just data points within current data models.”
“Simply put, pulsESG™ offers an integrated, comprehensive, and flexible SaaS platform for enterprises to define, capture, analyze, derive insight, and improve their ESG footprint,” added Murat Sönmez, Co-founder and CEO.
While private equity firms, their investors, and other stakeholders increasingly take ESG impacts and risk into account, the measurement tools and benchmarks for each continue to evolve—both across sectors and jurisdictions. Sönmez and Singh saw the opportunity to leverage their experience with SaaS platforms, integration, business processes, analytics, and master data management to create a system to help enterprises navigate and respond to this inherent fluidity in ESG analysis. The result of their vision is the pulsESG™ platform.
Sönmez and Singh have found early backing from leading investors in the impact-driven investment space, including FINTOP Capital, Aligned Climate Capital, SOMPO Holdings (Japan), Builders VC, eLab Ventures, and individual investors including Alberto Cribiore and André Borschberg.
Prior to co-founding pulsESG™, Murat Sönmez was a member of the founding team at TIBCO Software and led it past the billion-dollar revenue mark as the head of its customer facing operations. Sönmez later joined the Managing Board of the World Economic Forum in Switzerland, leading its global business community engagement efforts, and subsequently established and led its global technology policy network out of San Francisco.
pulsESG™ Co-founder Inderjeet Singh was most recently responsible for Oracle’s middleware and cloud platform and previously for TIBCO’s infrastructure products. Inderjeet joined TIBCO Software through the acquisition of Velosel—a leading master data management platform—where he was part of the founding team and led all product functions.
Investor Statements
“ESG reporting is quickly becoming standard practice for companies and investors worldwide. As an investor that cares deeply about ESG, we are excited about pulsESG’s ability to ensure that analysis and reporting is more real, reliable, and reportable."
— Peter W. Davidson, CEO, Aligned Climate Capital
"As one of the world’s largest economies, Japan faces pressure from an aging society with social impact and other ESG considerations steering business decisions more than ever. SOMPO has been working to address these issues in innovative ways and utilizing digital technologies to accurately measure our impact, so are excited to have found a partner in pulsESG—an integrated and comprehensive platform with the potential to accelerate SOMPO’s impact for society.”
— Kengo Sakurada, Group CEO, Director, President and Representative Executive Officer, SOMPO Holdings, Inc.
“In a crowded field of ESG platforms, Murat and Inderjeet stand apart with the completeness of their vision, passion for impact, and unparalleled combined experience in successfully scaling startups, developing mission-driven software platforms, and executing strategic engagement with top level leadership in organizations worldwide. We are pleased to lead the investment and look forward to an impactful journey together.”
— Rick Kushel, Co-founder and General Partner of FINTOP Capital
About pulsESG™
Founded in 2021, pulsESG, Inc. is a public benefit corporation dedicated to empowering purpose-driven enterprises to manage and improve their ESG footprint with an integrated and comprehensive SaaS platform built for compliance tracking and insight.
For more information: www.pulsESG.com
LinkedIn: www.linkedin.com/company/pulsESG
View source version on businesswire.com: https://www.businesswire.com/news/home/20211020005350/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom